États-Unis · Plateformes & données · Finviz

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Publié par Finviz · États-Unis il y a 3 j

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE)-- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

À lire aussi

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Partager

À lire aussi

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings